Background: The transition of prostate adenocarcinoma to a predominantly androgen receptor (AR)
Background:
Neuroendocrine prostate cancer (NEPC) is an aggressive, androgen receptor (AR) independent subtype of prostate cancer that most commonly becomes manifest in the later stages of castration resistant prostate cancer (CRPC) and is associated with treatment resistance (1) (2) (3) (4) (5) . The diagnosis of NEPC remains challenging and currently relies on a combination of pathologic and clinical features suggestive of AR signaling independence. Before NEPC develops, metastatic tumor biopsies often show mixed features with both adenocarcinoma and neuroendocrine carcinoma cells present. There are no reliable serum markers to consistently diagnose patients transforming to the NEPC phenotype and the incidence of circulating tumor cells (CTCs) in these patients is unknown. Detection of NEPC has clinical implications, as NEPC patients would not be expected to respond well to currently approved AR-targeted therapies for CRPC and may be better served by therapies specifically directed to NEPC.
CTCs provide the potential for non-invasive, real-time molecular characterization of cancer in patients with metastatic disease. To date, the only FDA-cleared test for CTC detection and enumeration is the CellSearch® technology, based on immunomagnetic enrichment of CTCs expressing the epithelial cell adhesion molecule (EpCAM). Several other platforms have recently been developed to improve sensitivity of CTC detection, most of which include enrichment and/or other physical selection methods (6, 7) . There is mounting evidence that non-traditional populations of CTCs also exist, including EpCAM/cytokeratin (CK)-negative CTCs (8) and/or cells smaller in size than traditional CTCs, some even smaller than neighboring white blood cells (6, 9) . The Epic Sciences platform is a non-selection based platform that characterizes all nucleated cells and identifies CTCs based on a multi-parametric digital pathology process identifying abnormal cells among the normal white blood cells utilizing protein expression and cell morphology (10) (11) (12) . This technique has demonstrated the ability to identify distinct CTC populations including traditional (CK+, CD45-), apoptotic, CK-negative, and CTC clusters (12, 13) . We aimed to characterize CTCs from patients with CRPC and NEPC 
Methods:

CTC collection
Under IRB approved protocols at Weill Cornell Medical College and Memorial Sloan Kettering Cancer Center, patients with metastatic CRPC including those with pure or mixed NEPC were prospectively enrolled. NEPC was defined by the presence of either a pure or mixed small cell high-grade neuroendocrine carcinoma histology in a metastatic tumor biopsy and confirmed by at least 20% positive immunohistochemical staining for a neuroendocrine marker (synaptophysin, chromogranin).
CRPC was defined clinically, with or without a metastatic biopsy confirming prostate adenocarcinoma.
CRPC patients were sub-classified as atypical CRPC if the biopsy showed adenocarcinoma and the patient had clinical features suggestive of an AR independent transition which included radiographic progression in the setting of a low PSA <1 ng/ml, visceral progression in the absence of PSA progression (defined by Prostate Cancer Working Group 2 criteria (14) and/or elevated serum chromogranin A >3X upper limit of normal.
Clinical demographics including prior therapies, sites of metastases, PSA, serum neuroendocrine marker levels, and CTC number (CellSearch®, Raritan, NJ) were collected. Blood (10 mL) from each subject was shipped to Epic Sciences within 48 hours and processed immediately on arrival. Red blood cells were lysed, approximately 3 million nucleated blood cells dispensed onto 10-16 glass slides as previously described (10) (11) (12) {Werner, 2015 #993} and placed at -80°C for long term storage. (CK), CD45, AR, and 4',6-diamidino-2-phenylindole (DAPI) counterstain. Slides were imaged using a platform that captures all 3 million cells per slide in less than 15 minutes, and analyzed by a 
CTC identification
Pathologic evaluation
Patient-matched metastatic tumor biopsies were reviewed by two anatomic genitourinary pathologists and classified as adenocarcinoma or NEPC based on presence of either pure or mixed small cell high grade neuroendocrine carcinoma histology in a metastatic tumor biopsy and confirmed by at least 20% positive immunohistochemical (IHC) staining for the neuroendocrine marker chromogranin and/or synaptophysin (15) . IHC was quantified on scale 0-3 and positive IHC was defined as any staining intensity seen of target cells above background. To assess AURKA amplification, we used a locus specific probe plus reference probe FISH assay as previously described (16) .
Statistical Analysis
CTC morphological/molecular data and clinical information were compiled into patient datasets (NEPC, CRPC, atypical CRPC) using KNIME, where cytokeratin expression, AR expression, presence of clusters and various nuclear and cytoplasmic morphological features were analyzed with single cell resolution ( distributions of CTC biomarkers were compared at the patient level for each diagnostic category.
Supervised learning was performed using the Random Forest classifier algorithm (R package 'randomForest') built with 1,001 decision trees and configured to provide a probability output (17) .
Leave-One-Out Cross-Validation
To evaluate the robustness of the Random Forest classifier, leave-one-out cross-validation was performed; CTCs from patients with atypical CRPC were removed from analysis, while CTCs from NEPC were labeled NEPC+ and CRPC were labeled NEPC-. Leave-one-out cross-validation at the blood sample level with the dataset partitioned into training and test sets is shown in Figures S1-3 , where atypical CRPC patients were excluded from the analysis. For each blood tube, CTCs from every other sample were used to train a classifier, and CTCs from the blood tube being evaluated were held-out as a test set. CTCs from the test set were analyzed by the trained classifier, where the output is an estimated probability of class membership to NEPC+ and NEPC-for each CTC belonging to the held-out sample. This cycle was repeated iteratively for each sample, and the classifier output was collected at the end of each iteration. The criteria for patient-level class membership was established as at least 3 CTCs with a p(NEPC) score greater than 0.95.
Atypical CRPC and Contemporary Cohort Analysis
A classifier was first trained on NEPC and CRPC samples, without atypical CRPC samples. This classifier was then used to classify the atypical CRPC sample CTCs, as well as CTCs from a 159 patient validation cohort. In the validation cohort, the same criteria for patient positivity (at least 3 CTCs with p(NEPC) greater than 0.95) was applied to generate patient-level predictions from the classifier's single-cell output. KDE curves were used to plot the distribution of NEPC+ class membership values for individual CTCs for each patient. 
Results:
CTCs from 27 patients with metastatic prostate cancer were evaluated. The patients identified either pathologically as NEPC (n=12) or clinically as atypical CRPC (n=5) as defined above demonstrated a higher frequency of liver metastases and lower PSA compared to other CRPC patients ( Table 1,   Table S2 ). Overall, bone metastases were present in 24/27 (88.9%) of patients, and liver metastases were present in 8/12 (66.7%) of NEPC and 5/15 (33.3%) of CRPC of whom 4 had atypical clinical features ( Table S3) . Median serum PSA level was 1.9 ng/ml in NEPC, 2.8 ng/ml in atypical CRPC, and 53.4 ng/ml in other CRPC patients. Serum neuroendocrine marker levels varied considerably within the NEPC subgroup and were also elevated in cases of CRPC.
CTCs in NEPC vs. CRPC
Enumeration of CTCs using both the CellSearch and Epic platforms was performed. Of note, 6/13 evaluated NEPC and atypical CRPC patients had CellSearch® CTC count of <5 CTC/7.5 mL (range 0-384, with 5 of these 13 patients having a CellSearch® CTC count of 0). In contrast, all 17 NEPC and atypical CRPC patients had CTCs >5 CTC/7.5mL using the Epic platform. Further characterization of the detected CTCs revealed heterogeneity of cytokeratin (CK) and AR expression in both NEPC and CRPC, with a significantly greater proportion of CK-negative and AR-negative CTCs in NEPC compared to CRPC (Figures 1-2, Table S4 ). CTCs in NEPC patients overall had lower AR expression, higher cytoplasmic circularity, and higher nuclear to cytoplasmic ratio. The prevalence of CK-negative CTC subpopulations in NEPC patients is potentially consistent with a proposed epithelial-mesenchymal-transition (EMT) (18, 19) .
Within the NEPC subgroup, there was a greater proportion of small cell CTCs in patients with metastatic biopsy confirming small cell carcinoma highlighting phenotypic similarities between tumor and CTCs. CTCs were tested by IF for the presence of the neuroendocrine marker CD56 ( Figure   3A CTCs, 7/12 (58%) had ≥1 CD56+ CTC and 0/8 (0%) non-neuroendocrine samples with detectable CTCs had ≥1 CD56+ CTC. Of patient samples with small cell carcinoma pathology by tumor biopsy, 5/7 (71%) had ≥1 CD56+ CTC. A confusion matrix demonstrates high specificity for small-cell NEPC patients, demonstrating concordance to tumor tissue (Table S5) . Additional molecular characterization of these CTCs using fluorescence in situ hybridization (FISH) for AURKA, a gene commonly amplified in NEPC (20) , showed concordance with matched metastatic biopsies in selected cases (an example is highlighted in Figure S4 ) but was not present in all cases or all cells in positive cases.
Based on the observed differences in CTCs between groups, we sought to identify CTC characteristics specific to NEPC, as described in the Methods. Cell-level features were utilized to train Random Forest cell-level classifiers in both the LOOCV and for the classification of CTCs in the test cohort are shown in Table S1 . KDE analysis of the patient groups' CTCs in aggregate revealed significant differences in CK, AR and morphological characteristics when compared to CRPC (Figures 2-3B) .
Identification of NEPC CTCs
To demonstrate the diagnostic potential of CTC characteristics in distinguishing NEPC, the observed differences between NEPC and CRPC were used to train a Random Forest classifier. Results from leave-one-out cross-validation of NEPC and CRPC samples are shown in Figures S5-S6 , where the output from the classifier is a p(NEPC+) value and a p(NEPC-) value for each CTC, corresponding to the estimated probability of the cell's class membership as NEPC+ and NEPC-.
From the density curve in Figure S4A , the samples from patients with NEPC demonstrated a spike in the curves near the high end of the p(NEPC+) spectrum, with many curves peaking near a p(NEPC+) score of 95%. In Figure S4B , the number of CTCs/mL with p(NEPC+) scores greater than or equal to 
Obtaining positive signals at the CTC level from samples that the classifier does not encounter during training demonstrates the classifier's ability to detect NEPC from CRPC in a robust manner that mitigates the risk of over-fitting. These conditions simulate the environment that the classifier would face in practice, in the sense that any future blood sample sent in for NEPC analysis is presented to the algorithm as a series of CTCs that it has not encountered during training, which the classifier will then estimate the probability of class membership for each CTC from the new sample.
Atypical CRPC
The clinical significance of patients with castration resistant adenocarcinoma that develop progressive disease in the setting of low serum PSA <1ng/ml, visceral metastases in the absence of PSA progression, or elevated serum chromogranin is not well established. One hypothesis is that these tumors are less androgen responsive and may be in transition towards an AR negative/low or NEPC phenotype and/or demonstrate intratumoral heterogeneity with both adenocarcinoma and NEPC present within or between metastases. We applied the NEPC classification model trained to distinguish NEPC vs. CRPC CTCs to the 5 atypical CRPC patients and found that atypical CRPC is associated with an increase in heterogeneity of CRPC cells and a higher burden of NEPC-like cells compared to CRPC patients ( Figure S4 , Table S6 ). Histologic and molecular subtyping of cancer often influences clinical decision making, and tissue confirmation is typically required at cancer diagnosis before treatment recommendations are offered.
Patient Case Studies
Prostate cancer is the most common cancer in men in the United States and Europe (21, 22) , and in nearly all cases diagnostic biopsies reveal adenocarcinoma upon initial diagnosis. Prostate adenocarcinomas are characterized by AR expression and activation, and therefore hormonal therapies targeting the AR are the mainstay of systemic therapy (23) . Small cell neuroendocrine carcinoma of the prostate is a rare histologic subtype at diagnosis, representing less than 1% of all new prostate cancer diagnoses (24) . However, in a subset of patients with metastatic prostate adenocarcinoma treated with AR targeted therapies, prostate adenocarcinomas can develop histologic transformation towards a predominantly neuroendocrine carcinoma likely as a mechanism of acquired resistance (1) (2) (3) (4) (5) . The NEPC phenotype is associated with aggressive disease, frequent visceral metastases, and low or absent AR expression on metastatic tumor biopsy(4). In this setting, patients are often offered platinum based chemotherapy with regimens similar to small cell neuroendocrine carcinoma of the lung (25, 26) . Therefore, identification of advanced prostate cancer patients that have acquired NEPC has potential clinical implications.
However, the diagnosis of NEPC can be complex as there is a spectrum of morphologies seen in 
of appropriate systemic therapy, and does not always capture disease heterogeneity.
Therefore, a noninvasive marker to detect NEPC progression and simultaneously capture intrapatient heterogeneity is an unmet need.
We found that CTCs from metastatic prostate cancer patients are often phenotypically heterogeneous.
CTCs from patients with pathologically confirmed NEPC were predominantly of smaller size compared to other CRPC patients and demonstrated lower AR expression and abnormal nuclear and cytoplasmic features. There was also a higher prevalence of low cytokeratin expressing CTCs in NEPC, possibly related to EMT changes that can occur during metastatic transit and treatment resistance (27, 28) . When applied to an independent cohort, we found that up to 10% of CRPC patients also harbored similar NEPC+CTC subpopulations and their presence was associated with aggressive clinical features (ie., visceral metastases, high CTC burden). These data support the possible detection of circulating neuroendocrine cancer cells in patients with metastatic CRPC; however, the lack of definitive markers and mixed cellular subpopulations observed reinforce the biologic and clinical complexity underlying disease progression and NEPC transformation. Differences in nuclear size may also be contributed by the presence of visceral metastases as has been recently observed by Chen et al (29) . What remains unclear are the dynamics by which these CTCs arise and how the classifier performs as a predictive or prognostic biomarker. Serial monitoring of CTCs in larger cohorts could help elucidate how consistently the classifier emerges during the course of therapy and during the CRPC-to-NEPC transition. Future studies including single cell sequencing of CTCs will also be important to molecularly characterize these heterogeneous populations and may improve our understanding of this complex resistance phenotype. 
